Please use this identifier to cite or link to this item:
|Title:||Sites of actions of alpha 2 agonists in the brain and periphery.|
|Authors:||Louis, William J;Jarrott, B;Conway, Elizabeth L|
|Affiliation:||Clinical Pharmacology and Therapeutics Unit, Austin Hospital, Heidelberg, Victoria, Australia.|
|Citation:||The American Journal of Cardiology; 61(7): 15D-17D|
|Abstract:||Alpha 2 agonists including rilmenidine, clonidine and alpha methylnoradrenaline all seem to have a predominantly central action in lowering blood pressure. Studies using the peripheral decarboxylase inhibitor alpha-methyldopa hydrazine in both experimental animals and humans support the predominant central action of the active metabolite of methyldopa, alpha methylnoradrenaline. Comparative studies on the antihypertensive potency of selective alpha 2 agonists like rilmenidine, guanfacine, clonidine and lofexidine suggest that the relative ability to bind to alpha 1 and alpha 2 adrenoceptors is not critical but the ability to enter the central nervous system is essential for antihypertensive efficacy.|
|Internal ID Number:||2894151|
Blood Pressure.drug effects
Receptors, Adrenergic, alpha.metabolism.physiology
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.